ClinicalTrials.gg
CompletedNCT06143046Updated Jun 10, 2026

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

A Phase 2 interventional study of mRNA-1345 and Placebo in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 56 sites in 8 countries. Open to participants aged 0 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
0 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.

Enrollment
8th of 10
360 · median 579
Started
2023
with 3 others
Phase 2
2 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
10 of 10
ModernaTX, Inc.

Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 8th largest by enrollment, is one of 4 that started in 2023, is one of 2 in phase 2, and was the 9th registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →

About mRNA-1345 respiratory syncytial virus vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 0 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases as a file.
02

Study summary

The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers.

03

Conditions studied

  • Respiratory Syncytial Virus

Browse trials for

Keywords

  • mRNA-1345
  • RSV vaccine
  • Viral Diseases
  • Messenger RNA
  • Moderna
04

Who can participate

Ages eligible
0 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Maternal Participants

  • Are adults ≥18 years to \<40 years of age inclusive, at the time of signing the .
  • Will be 28 to 36 weeks pregnant at the time of vaccination (confirmed by an obstetric ultrasound report).
  • Intend to deliver at a maternity unit where study procedures can be performed.
  • Are willing and able to attend all study visits, to undergo all study procedures/or have their infant undergo all study procedures, and to comply with study requirements, including a means of communication (for example, phone, text message or email) with study site staff.
  • Have engaged with local antenatal care and will continue to do so through the remainder of their pregnancy.
  • Have had an antenatal obstetric ultrasound at ≥18 weeks of pregnancy or be willing to have an antenatal obstetric ultrasound at Screening if not already conducted.

Specific inclusion criteria for Japanese pregnant women:

  • Japanese participants are defined as individuals born in Japan, with both parents and 4 grandparents who were born in Japan.

Infant Participants

  • Have consent from infant participant's parent(s)/legally authorized representative (LAR) if required by local regulations.

Key Exclusion Criteria:

Maternal Participants

  • Acutely ill or febrile (temperature ≥38.0 degrees Celsius [℃]/100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1.
  • Reported history of anaphylaxis or severe reaction after receipt of any mRNA vaccine or therapeutic or any components of an mRNA-1345 vaccine.
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Have conditions in the current pregnancy or in previous pregnancies that may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  • Received or plans to receive any mRNA vaccine or COVID-19 vaccine within 4 weeks before or after Day 1 and/or any other nonstudy vaccine within 2 weeks before or after Day 1.
  • Previous vaccination with any licensed or RSV vaccine or planned receipt during study participation.
  • Intend for their infant to receive RSV monoclonal antibodies after delivery.

Infant Participants

  • Is a child who has been placed under the control or protection of an agency, organization, institution, or entity by the courts, the government, or a government body acting in accordance with powers conferred on them by laws and regulation (for example, foster care). This does not include a child who is adopted or has an appointed LAR.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    mRNA-1345 Dose A

    Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single intramuscular (IM) injection of mRNA-1345 Dose A.

    Biological: mRNA-1345

  • Experimental
    mRNA-1345 Dose B

    Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single IM injection of mRNA-1345 Dose B.

    Biological: mRNA-1345

  • Experimental
    mRNA-1345 Dose C

    Participants will be vaccinated in the period from 28 weeks to 36 weeks of gestation with a single IM injection of mRNA-1345 Dose C.

    Biological: mRNA-1345

  • Placebo comparator
    Placebo

    Participants will receive single IM injection of mRNA-1345 vaccine matching placebo in the period from 28 weeks to 36 weeks of gestation.

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Maternal Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 7 (7 days post vaccination)

  2. Number of Maternal Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 28 (28 days post vaccination)

  3. Number of Maternal Participants with Medically-Attended AEs (MAAEs)

    Time frame: Day 1 to Month 6 (6 months postdelivery)

  4. Number of Maternal Participants with Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 to Month 12 (12 months postdelivery)

  5. Number of Maternal Participants with Serious Adverse Events (SAEs)

    Time frame: Day 1 to Month 12 (12 months postdelivery)

  6. Number of Maternal Participants with AEs Leading to Discontinuation

    Time frame: Day 1 to Month 12 (12 months postdelivery)

  7. Number of Maternal Participants With Pregnancy Outcomes

    Pregnancy outcomes will include stillbirth, live birth, vaginal delivery, and cesarean section delivery.

    Time frame: Day 1 to Month 12 (12 months postdelivery)

  8. Number of Infant Participants with MAAEs

    Time frame: Day 1 (birth) to Month 12

  9. Number of Infant Participants with AESIs

    Time frame: Day 1 (birth) to Month 12

  10. Number of Infant Participants with SAEs

    Time frame: Day 1 (birth) to Month 12

  11. Number of Infant Participants With Birth Outcomes

    Birth outcomes will include gestational age and anthropometric measurements.

    Time frame: Day 1 (birth) to Month 12

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Serum RSV-A and RSV-B Neutralizing Antibodies in Maternal Participants

    Time frame: Day 1, Day 29, delivery, and Month 6 (6 months postdelivery)

  2. Geometric Mean Concentration (GMC) of Serum RSV-F Binding Antibodies in Maternal Participants

    Time frame: Day 1, Day 29, delivery, and Month 6 (6 months postdelivery)

  3. Geometric Mean Fold-Rise (GMFR) of Postbaseline/Baseline Neutralizing Antibody Titers and Binding Antibody Concentrations in Maternal Participants

    Time frame: Day 29, delivery, and Month 6 (6 months postdelivery)

  4. Percentage of Maternal Participants With ≥4-fold Increase From Baseline in Neutralizing Antibody Titers and Binding Antibody Concentrations

    Time frame: Baseline up to Month 6 (6 months postdelivery)

  5. GMT of Serum RSV-A and RSV-B Neutralizing Antibodies in Infant Participants

    Time frame: Day 1 (birth), and Months 2, 6, and 12

  6. GMC of Serum RSV-F Binding Antibodies in Infant Participants

    Time frame: Day 1 (birth), and Months 2, 6, and 12

07

Study locations

56 sites
  • SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS
    Dothan, Alabama 36305-7376, United States
  • Abby's Research Institute
    Phoenix, Arizona 85031-3878, United States
  • Watching Over Mothers & Babies
    Tucson, Arizona 85712, United States
  • Applied Research Center of Arkansas - ClinEdge - PPDS
    Little Rock, Arkansas 72212-4169, United States
  • Matrix Clinical Research - Gardena
    Gardena, California 90247-4956, United States
  • Matrix Clinical Research - Huntington Park
    Huntington Park, California 90255-2913, United States
  • Matrix Clinical Research, Inc - Corporate Office
    Los Angeles, California 90057-4103, United States
  • Clinical Research Prime - ClinEdge - PPDS
    Idaho Falls, Idaho 83404-5305, United States
  • Bingham Memorial Hospital
    Pocatello, Idaho 83201, United States
  • Clinical Research Prime - ClinEdge - Rexburg - PPDS
    Rexburg, Idaho 83440-5390, United States
  • Velocity Clinical Research - Covington - PPDS
    Covington, Louisiana 70433-7237, United States
  • Saginaw Valley Medical Research Group LLC
    Saginaw, Michigan 48604-9533, United States
  • Boeson Research GTF - Great Falls - ERN - PPDS
    Great Falls, Montana 59405-5316, United States
  • Boeson Research KAL - Kalispell - ERN - PPDS
    Kalispell, Montana 59901-2158, United States
  • Boeson Research MSO - Missoula - ERN - PPDS
    Missoula, Montana 59804-7401, United States
  • Velocity Clinical Research (Grand Island - Nebraska) - PPDS
    Grand Island, Nebraska 68803-4327, United States
  • Velocity Clinical Research (Hastings - Nebraska) - PPDS
    Hastings, Nebraska 68901-2615, United States
  • Velocity Clinical Research (Norfolk - Nebraska) - PPDS
    Norfolk, Nebraska 68701-7701, United States
  • DM Clinical Research - Bellaire - ERN - PPDS
    Houston, Texas 77081, United States
  • Maximos OB/GYN
    League City, Texas 77573-2681, United States
  • SMS Clinical Research
    Mesquite, Texas 75149, United States
  • Maternal Fetal Diagnostics Center
    Salt Lake City, Utah 84132-0001, United States
  • Dalhousie University - 5820 University Ave
    Halifax, Nova Scotia B3H 1, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Sainte Justine Hospital
    Montreal, Quebec H3T 1C5, Canada
  • Centre Hospitalier de l'Université Laval
    Québec, G1V 4G2, Canada
  • Clínica Universidad de los Andes
    Las Condes, Región-MetropolitanadeSantiago 7550000, Chile
  • Centro Internacional de Estudios Clínicos
    Recoleta, Región-MetropolitanadeSantiago 8420000, Chile
  • Red Hospital Clinico de la Universidad de Chile
    Santiago, 8380453, Chile
  • Hvidovre Hospital
    Hvidovre, Capital DK-2650, Denmark
  • Aarhus Universitetshospital
    Aarhus, Central Jutland 8200, Denmark
  • Regionshospitalet Gødstrup
    Herning, Central Jutland 7400, Denmark
  • Shonan Kamakura General Hospital
    Kamakura-Shi, Kanagawa 247-8533, Japan
  • Saiseikai Yokohamashi Nanbu Hospital
    Yokohama, Kanagawa 234-0054, Japan
  • Saitama City Hospital
    Saitama-Shi, Saitama 336-0911, Japan
  • Center Hospital of the National Center for Global Health and Medicine
    Shinjuku-Ku, Tokyo 162-8655, Japan
  • Centro De Vacunacion Internacional, S.A. (Cevaxin) - David
    David, Chiriquí Province, Panama
  • Centro De Vacunacion Internacional, S.A. (Cevaxin) Sede La Chorrera
    Panama City, Panama
  • Centro De Vacunacion Internacional, S.A. (Cevaxin)
    Panama City, Panama
  • CEVAXIN 24 de diciembre
    Panama City, Panama
  • Instituto de Investigaciones Científicas Y Servicios de Alta Tecnología Asociación de Interés Panama
    Pueblo Nuevo, Panama
  • Josha Research
    Bloemfontein, Free State 9300, South Africa
  • Drs. YAK Vahed & Partners
    Welkom, Free State 9459, South Africa
  • Ubuntu Clinical Research
    Krugersdorp, Gauteng 1739, South Africa
  • Bothe ke Bontle Health Services-316 Kuit st
    Pretoria, Gauteng 0184, South Africa
  • Setshaba Research Centre
    Soshanguve, Gauteng 152, South Africa
  • WITS Clinical Research Site - PPDS
    Soweto, Gauteng 2013, South Africa
  • Merclinico Middelburg
    Middelburg, Mpumalanga 1050, South Africa
  • FAM-CRU
    Cape Town, Western Cape 7505, South Africa
  • Royal Bournemouth Hospital
    Bournemouth, Dorset BH7 7DW, United Kingdom
  • Southampton General Hospital
    Southampton, Hampshire, United Kingdom
  • The Royal London Hospital
    London, London, City of E1 1FR, United Kingdom
  • The Royal Free Hospital
    London, Middlesex NW3 2QG, United Kingdom
  • Cardiff & Vale University Health Board-PPDS
    Cardiff, South Glamorgan CF14 4XN, United Kingdom
  • St George's Hospital
    London, Surrey SW17 0QT, United Kingdom
  • Glasgow Clinical Research Facility - PPDS
    Glasgow, G51 4TF, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in May 2026, 30 months.

Of 34 industry-sponsored phase 2 interventional studies under Virus Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 30 months is above that.

Counting every sponsor, half of 58 studies reached it within 16 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 22, 2023
StartActual
Nov 15, 2023
Primary completionActual
May 25, 2026
CompletionActual
May 25, 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06143046
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Nov 15, 2023
Primary completion
May 25, 2026
Completion
May 25, 2026
Last update
Jun 10, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine

Start the discussion